Squarepoint Ops LLC Raises Stock Holdings in CryoPort, Inc. $CYRX

Squarepoint Ops LLC boosted its stake in shares of CryoPort, Inc. (NASDAQ:CYRX) by 685.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 368,424 shares of the company’s stock after acquiring an additional 321,497 shares during the quarter. Squarepoint Ops LLC’s holdings in CryoPort were worth $5,784,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of CYRX. UBS Group AG boosted its holdings in CryoPort by 112.7% during the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after buying an additional 705,649 shares in the last quarter. Millennium Management LLC grew its stake in CryoPort by 23.8% in the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after acquiring an additional 623,896 shares during the period. Wellington Management Group LLP acquired a new position in CryoPort in the 2nd quarter valued at $8,398,000. Jacobs Levy Equity Management Inc. lifted its stake in shares of CryoPort by 283.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock worth $4,970,000 after purchasing an additional 387,440 shares during the period. Finally, Mak Capital One LLC grew its position in shares of CryoPort by 46.6% in the fourth quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock valued at $11,513,000 after purchasing an additional 381,063 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity at CryoPort

In other news, CEO Jerrell Shelton sold 28,800 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total transaction of $429,408.00. Following the transaction, the chief executive officer directly owned 1,201,814 shares of the company’s stock, valued at approximately $17,919,046.74. The trade was a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on CYRX shares. KeyCorp increased their target price on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Weiss Ratings lowered shares of CryoPort from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 17th. Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a report on Monday, June 8th. Craig Hallum boosted their price objective on shares of CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, June 3rd. Finally, Needham & Company LLC lifted their target price on CryoPort from $15.00 to $19.00 and gave the company a “buy” rating in a report on Friday, August 7th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $18.00.

CryoPort Stock Performance

CYRX stock opened at $15.55 on Friday. The firm has a market cap of $787.61 million, a P/E ratio of -17.28 and a beta of 1.89. CryoPort, Inc. has a 1 year low of $7.61 and a 1 year high of $17.20. The stock has a 50-day simple moving average of $15.68 and a 200-day simple moving average of $13.04.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $48.97 million during the quarter, compared to analysts’ expectations of $48.18 million. CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%. On average, equities research analysts predict that CryoPort, Inc. will post -0.83 EPS for the current year.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.